RWE and Patient-Centered Outcomes
Widespread availability of real-world data has enabled the generation of evidence and insights that benefit patients, providers, plans, and industry. When that evidence reflects patient outcomes, it provides an invaluable perspective on the consumer experience. Explore our real-world evidence (RWE) analyses and guidance to support your strategic decisions.
Beyond Plug-and-Play: Elevating HEOR to Enterprise-Level Impact
Successful HEOR teams are increasingly aligning evidence generation strategies with cross-enterprise teams to maximize their impact.
Multi-Stakeholder Collaboration in Rare Diseases: The Role of Clinicians Within and Beyond the Clinic
Clinicians can support timely, sustainable rare disease care through institutionalized multi-disciplinary roles, strengthened referral networks, and the translation of clinical insights into policy and advocacy.
eBook: Rare Disease Biotech Landscape, 2026
Rare disease demands a unique playbook: The patient journey is rarely linear, the evidence base is often limited, and “rare” can have different meanings across settings and geographies. The third edition of our annual rare disease eBook explores the unique dynamics of the rare disease landscape and its implications for biotech stakeholders.
Gene Therapy in Rare Disease: From Breakthrough to Stewardship
As gene therapies for rare diseases scale, system readiness and long-term stewardship–not science alone–will determine access, impact, and sustainability.
Amplifying Rare Disease Patient Groups in APAC
Rare disease patient groups in APAC can amplify their impact through multi-stakeholder collaboration to achieve equitable access for people living with rare diseases.
RWD Integration in Reimbursement Decisions across EU4 and the UK
European countries are advancing real-world data use in healthcare decision-making, but face challenges from differing national frameworks and regulations
Sociodemographic Factors and Healthcare Costs Among Rare Epilepsies
Distinct patient characteristics and cost profiles across rare epilepsies reinforce the value of disease-specific approaches in rare disease research.
Novel Antibiotic Use Is Low, Even for Complex Cases
An Avalere Health analysis determined that less than 1% of patients with community-acquired bacterial pneumonia were treated with novel antibiotics.
Belief Mapping: Elevating Value Engagement Strategies
Uncovering beliefs underpinning payer decision making can help global access teams achieve optimal and equitable patient access, faster.
Healthcare Utilization and Costs for Patients with Transfusion Dependent β-thalassemia Following Luspatercept Use
A retrospective FFS claims analysis of adults with β-thalassemia found limited differences in most related healthcare resource utilization or cost categories before and after luspatercept use among those with transfusion-dependent β-thalassemia.
Unlocking Global Access to GLP-1 AOMs Requires Moving Beyond Disease Recognition to Demonstrating Broader Value
To enable global access to GLP-1 AOMs, manufacturers must demonstrate multidimensional value along the full care continuum and across the range of obesity linked-indications.
Video: Inside Compendia: Off-Label Applications
Avalere Health Advisory experts discuss how compendium shape off-label drug use, underscoring both benefits and risks in clinical decision-making.
EHDS Aims to Transform Data Access Across EU Health Systems
The European Health Data Space aims to enable secure, unified health data access across Europe, supporting research, innovation, and improved patient outcomes.
Video: Inside Compendia: Expanding Intended Use Populations
In the second installment of our Inside Compendia series, Avalere Health Advisory experts discuss how compendia can support clinical decision-making and medication access, highlighting a case study on GLP-1s.
Strategic Entry Points for Shaping USPSTF Recommendations
Avalere Health helps innovators shape USPSTF recommendations, driving preventive care access, payer coverage, and clinical adoption.
White Paper: Estimated Federal Savings from the Special Diabetes Program
Avalere Health finds that research funded by the Special Diabetes Program has yielded more than $50 billion in federal healthcare savings
White Paper: The Cost of Opioid Use Disorder
Avalere Health finds opioid use disorder costs businesses, governments, and households almost $1 trillion per year, but treatment with medications can lower costs.
RWE Data Management Lessons Applicable to NIH Autism Database
The NIH recently announced plans to develop an RWE database to study autism spectrum disorders. In doing so, they can learn lessons encountered by life sciences companies developing data ecosystems for their products.
Manufacturers Must Adapt to Growing GLP-1 and GIP/GLP-1 RA Markets
As the GLP-1 product market continues to expand, manufacturers must find ways to differentiate their inline and pipeline assets with new evidence and strong value story.
National Kidney Month: Setting the Stage for 2025 Changes
Political changes, transplant system reforms, research advancements, and expanded CKD indications create opportunities and challenges in the kidney care space.